MIV Therapeutics says research demonstrates superiority of its coronary stent covering

By Lisa Kerner

Charlotte, N.C., June 20 - MIV Therapeutics, Inc. said recent research on hydroxyapatite (HAp) coatings for stents shows the company's proprietary coatings for coronary stents outperformed other technologies and products currently in use.

The presentation showed that HAp remains highly biocompatible independent of the presence or absence of drugs within the coating, enabling it to outperform polymer-based coatings that rely on drugs to maintain acceptable coating performance.

"Our comprehensive testing and evaluation program continues to evaluate performance of our coating and drug delivery technologies in preparation for clinical trials scheduled to commence in the near future," chief technology officer Arc Rajtar said in a company news release.

"We are methodically completing steps necessary to enter this decisive phase leading towards successful commercialization of our technologies."

The data was presented at the 29th Conference of the Canadian Medical and Biological Engineering Society.

Located in Vancouver, B.C., MIV develops biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.